DGDeena Godfrey

Deena Godfrey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deena Godfrey has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Automated extraction of seizures and ictal-interictal continuum patterns from EEG reports to enable large-scale neurophysiology and neurocritical care research

    by Shadi Sartipi, Deena S. Godfrey, Alexandra-Maria Tauțan, Marta P. Fernandes, Manohar Ghanta, Aditya Gupta, Bruce Nearing, Jennifer Kim, Aaron F. Struck, Tobias Loddenkemper, et al.

  • Open Access

    Patterns and Clinical Predictors of Antiseizure Medication Use in Pediatric Traumatic Brain Injury

    by Deena S Godfrey, Marta Fernandes, Kevin J Staley, Ann-Christine Duhaime, Sahar F Zafar

    Objective Current guidelines recommend the use of antiseizure medications (ASM) in pediatric patients with severe traumatic brain injury (TBI). This is based on low-quality evidence and can lead to variability in practice and over-prescription of medications. To understand factors influencing ASM prescription in pediatric TBI, we examined clinical variables associated with inpatient and discharge ASM prescription. Methods Multi-center, retrospective cohort study of patients aged 0 to 21 years, admitted with TBI to the intensive care units at two Level I trauma centers, from 2016 through 2024. Obtained demographic and clinical information from chart review. Neuroimaging and electroencephalogram findings were extracted from reports. Primary outcome measure was ASM administration during inpatient hospitalization. Secondary outcome measure was prescription of ASMs at discharge. We developed multivariable logistic regression models to identify factors associated with inpatient and discharge ASM prescription, and report adjusted odds ratios (OR) with 95% confidence intervals (CI). Results 467 patients met inclusion criteria. 287 (61%) patients were given an ASM during their hospitalization, and 159 (34%) patients were discharged from the hospital on an ASM. Factors associated with higher likelihood of inpatient ASM prescription include intracranial injury on imaging (OR 57, 95% CI 24–156), moderate Glasgow Coma Scale score of 9 to 12 (OR 21, 95% CI 2.4–354), neurology/neurosurgery admission (OR 11, 95% CI 3.1–42), and immediate seizures (OR 3.6, 95% CI 0.77-23). Clinical factors associated with greater likelihood of discharge ASM prescription were neuroimaging abnormalities (OR 8.5, 95% CI 4.0–20), immediate seizures (OR 6.1, 95% CI 1.9–22), and neurology/neurosurgery admission (OR 2.1, 95% CI 0.71–6.8). Conclusions Neuroimaging abnormalities, seizures, and admission to neurology or neurosurgery services were associated with greater likelihood of ASM prescription during hospitalization and at discharge. Future studies are needed to determine whether ASM prescription improves outcomes and optimize ASM use.

  • Association Between Plasma Glial Fibrillary Acidic Protein, Ubiquitin Carboxy-Terminal Hydrolase-L1, S100B, and High-Sensitivity C-Reactive Protein Levels, Clinical Findings, and Imaging Abnormalities in Children with Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study

    by Deena Godfrey, Michael Bambrick, Gillian Hotz, Sonia Jain, Esther L. Yuh, Sandra Rincon, Xiaoying Sun, Carla Fortes, Geoffrey T. Manley, Ann-Christine Duhaime

    Blood-based biomarkers have shown utility in discriminating adult patients with and without traumatic brain injury (TBI). Biomarker levels vary with severity, time since injury, and imaging findings (computed tomography [CT] and magnetic resonance imaging [MRI]). However, the association of specific biomarkers with clinical and imaging findings in children across the age spectrum and with different injury severities and presentations is not fully understood. To better characterize biomarker and clinical associations, we studied pediatric blood biomarker patterns within the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study (ClinicalTrials.gov #NCT02119182). TRACK-TBI is an observational multisite study that prospectively enrolled TBI patients across the lifespan and injury spectrum, from 2014 through 2018. Two centers enrolled children (ages 0–17 years). All participants underwent a head CT or MRI at the discretion of treating clinicians as part of acute clinical care, and the majority underwent a study MRI 2 weeks after injury. For this TRACK-TBI pediatric cohort, blood sampling was optional with informed consent provided by guardians. For the purposes of this study, only pediatric subjects with study-specific neuroimaging and plasma biomarkers were included. Plasma biomarkers assessed included glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), and high-sensitivity C-reactive protein (hsCRP). Biomarker levels were compared between participants with and without radiographical traumatic intracranial findings (day-of-injury CT-positive versus CT-negative and 2-week study MRI-positive versus MRI-negative) and between participants with different clinical indices of injury. Of 158 pediatric participants, 75 consented to blood collection and underwent biomarker analysis. Of these, 65 had acute CT scans (within 24 h of injury) and 43 had standardized study-related MRI scans at 2 weeks (±3 days) from injury; thus, 70 subjects had biomarker levels and study-reviewed CTs and/or MRIs and are included in the present analysis. Univariate analyses showed significant differences in plasma GFAP, UCHL1, S100B, and hsCRP with respect to time since injury and CT findings. GFAP levels differed by Glasgow Coma Scale (GCS) severities and MRI findings; S100B levels differed by GCS and loss of consciousness. Multivariable linear regression models confirmed a significant association of GFAP, UCH-L1, and S100B levels with CT-positive findings and a significant association of GFAP with 2-week MRI-positive findings. Among the biomarkers evaluated in our study, GFAP was the strongest predictor of imaging findings using receiver operating characteristic analysis. Significant age effects were seen for S100B and NSE, with higher values in younger children. Multivariable associations were observed for specific day-of-injury plasma biomarkers and radiographical traumatic intracranial findings on CT and MRI in children with acute TBI. These biomarkers have potential utility to aid in TBI screening by helping to triage which patients are likely to have intracranial findings on neuroimaging.

  • Open Access

    Release of Extracellular Matrix Components after Human Traumatic Brain Injury

    by Michael Bambrick, Deena Godfrey, Mark D. Johnson, Jeffrey D. Esko, Biswa Choudhury, Alejandro Gomez Toledo, Mousumi Paulchakrabarti, Carla Fortes, Kevin J. Staley, Ann-Christine Duhaime

    Animal studies and human tissue experiments have demonstrated that traumatic brain injury (TBI) causes damage to the extracellular matrix (ECM). To test the hypothesis that TBI causes disruption of sulfated glycosaminoglycan (sGAG) in the ECM, we measured levels of sGAG in the cerebrospinal fluid (CSF), blood, and urine, in patients with severe TBI in the acute postinjury period. Samples of CSF, blood, and urine were obtained within 72 h of injury in patients who received external ventricular drains as part of their treatment of severe TBI. Levels of chondroitin and heparan sGAGs were measured, along with their disaccharide constituents. Demographic information, presence of polytrauma, brain injury load, and distance of radiologically visible parenchymal injury from the ventricle were analyzed for correlation with total subtype sGAG levels. Levels were measured in 14 patients ranging in age from 17 to 90 years. CSF sGAG levels were variable among patients, with higher sGAG levels in plasma compared with CSF. Patients with polytrauma had nonsignificantly higher blood sGAG compared with patients with isolated head injury. Subcategories of CSF sGAG levels correlated with distance from the ventricle of parenchymal injury but not with brain injury load. This study is the first to measure sGAG levels in ventricular CSF and the first to analyze levels in TBI. These data demonstrate the elevation locally of intracranial sGAGs after severe TBI and suggest rapid local metabolism of these breakdown products. The consequences of ECM breakdown may provide unique therapeutic and preventive avenues to mitigate postinjury sequelae.


  • Open Access

    Monogenic Causes of Cerebrovascular Disease in Childhood: A Case Series

    by Bridget E.L. Ostrem, Deena Godfrey, Paul A. Caruso, Patricia L. Musolino


  • A 7-year old female with arthrogryposis multiplex congenita, Duane retraction syndrome, and Marcus Gunn phenomenon due to a ZC4H2 gene mutation: a clinical presentation of the Wieacker-Wolff syndrome

    by Deena Godfrey, Alcy Torres, Gena Heidary, Hovra Zahoor, Arthur Lee, Gerard Berry, Elizabeth Engle

    Background: Duane retraction syndrome and arthrogryposis multiplex congenita have an incidence of approximately 1:1500–1:3000 live births. However, the association of these two entities with a Marcus-Gunn might be a rare and, until now, under-recognized clinical presentation of the Wieacker-Wolff Syndrome. Patient and methods: We report a 7-year-old female with dysmorphic features, global developmental delay, arthrogryposis multiplex congenita (AMC), Duane retraction syndrome (DRS), and unilateral Marcus Gunn jaw winking. Results: Whole Exome Sequencing showed a de novo premature stop codon in ZC4H2. Extensive genetic and metabolic work was negative otherwise and Brain MRI showed delayed non-specific myelination abnormalities. She continues to have significant delays but does not have regression, seizures or other neurological complications. She has required a multidisciplinary approach for the management of her multiple contractures. Conclusion: This case confirms ZC4H2 as a cause of syndromic DRS and extends the ZC4H2 phenotype to include Marcus Gunn jaw winking.


  • Triad of hypovitaminosis A, hyperostosis, and optic neuropathy in males with autism spectrum disorders

    by Deena Godfrey, Robert T. Stone, Marcus Lee, Tanuja Chitnis, Jonathan D. Santoro

    Persons with autism spectrum disorder (ASD) can have restrictive diets due to stereotyped behaviors. These restrictive diets can manifest with nutritional deficiencies, such as Vitamin A deficiency...